ÃâÒßѧÊÔÌâ
UjUDP>iz.> Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£©
/mF%uI>: 1. Fas(CD95)/FasL
89?AcZ.D 2. common chain of cytokine receptor
d 6j'[ 3 . TCR/CD3 complex
<Hig,(=`. 4. negaive selection of thymocytes
ze{ 5. artificial active immune
l0l2fwz( 6. anti-idiotypic
2y`rS
_2 7. IgSF
o&-q.;MY 8. Integrin
[2WJ>2r}6 9. chemokine
?L|m:A` 10. B7/CD28
DfXXN ¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²60·Ö£©
]Wa.k 1. ±È½ÏMHC¢ñºÍMHC¢òÀ࿹ԲÎÓëµÄ¼Ó¹¤Ìá³Ê¿¹ÔµÄ¹ý³Ì¡£
ckHHD| 2. ±È½ÏCTLºÍNKɱÉ˰Ðϸ°ûʱʶ±ðºÍɱÉË»úÖÆµÄÌØµã¡£
2zZ" }Zr# 3. ±È½ÏÃâÒßѧ¼ì²â·¨ºÍÉúÎïѧ»îÐÔ¼ì²â·¨¼ì²âϸ°ûÒò×ÓµÄÓÅȱµã¡£ 4. ·¢ÏÖÒ»ÖÖеİ×ϸ°û·Ö»¯¿¹Ô»òÖ×ÁöÏà¹Ø¿¹Ô,²¢ÖƱ¸Á˵¥¿Ë¡¿¹Ìå,ÊÔÉè¼ÆÊµÑé·½°¸¿Ë¡´Ë»ùÒò¡£
|W[BqQIf 5. Ñ¡ÔñÏÂÊöÖÐÒ»¸öרÌâ,ÐðÊöÎÒ¹úÔÚÕâÒ»Ñо¿ÁìÓòµÄÏÖ×´¼°ÃæÁÙµÄÌôÕ½
)#%k/4(Y
07:CcT 1)Ö×ÁöÃâÒߣ»(2)»ùÒòÖÎÁÆ£»(3)CD¿¹Ô¡£
0O5(\8jM µÚËľüÒ½´óѧһ¾Å¾ÅÆßÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÃâÒßѧÊÔÌâ
tF}Vs} Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£©
Vcm9:,Xlw 1. B7/CD28
+l+8Z:i< 2. Th1 subset
38ChS.( 3. seven predicated transmembrane domain receptor superfamily£¨STR superfamily£©
kC"lO' 4. antibody affinity maturation
v1*Lf/ 5. AP-1
16Ym*kWIps 6. single chain variable fragment£¨ScFv£©
J$JXY@mBSC 7. NK cell receptor
2Z!%Q}Do 8. Zinkernagel-Doherty phenomenon
)FVW/{NF@q 9. Ig fold
1iyd{r7| 10. CD40/CD40L
@62QDlt; ¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²36·Ö£©
a7KP_[_( 1. ÊÔÊöÐØÏÙ΢»·¾³¶ÔÐØÏÙϸ°ûµÄÑ¡Ôñ×÷Óü°ÆäÓëTϸ°û¹¦ÄÜÐÔÑÇȺÐγɵĹØÏµ¡£
hYOUuC 2. ÊÔÊöÌåÒºÃâÒßÓ¦´ðµÄ¹æÂÉ£¬»ØÒä·´Ó¦ºÍ¿¹ÌåÀà±ðת»»µÄ»úÖÆÊÇʲô£¿
f-!t31?XK 3. ÊԴӽṹºÍ¹¦ÄܵȽǶȣ¬²ûÊö°×ϸ°û·Ö»¯¿¹Ô£¨CD£©¡¢Õ³¸½·Ö×Ó£¨integrin£©ºÍÃâÒßÇòµ°°×³¬¼Ò×壨IgSF£©ÈýÀà·Ö×ÓµÄÏ໥¹ØÏµ¡£Ä¿Ç°ÔÚÕâÒ»ÁìÓòÖÐÖ÷ÒªÑо¿ÈȵãÊÇʲô£¿
9,g &EnvG Èý. ÎÊ´ðÌ⣨24·Ö£¬µÚ1ÌâΪÃâÒßѧרҵ¿¼ÉúÊÔÌ⣬µÚ2ÌâΪѪҺ²¡Ñ§¿Æ¿¼ÉúÊÔÌ⣬µÚ3ÌâΪÏû»¯ÄÚ¿Æ¿¼ÉúÊÔÌ⣬ֻÔÊÐí´ð±¾×¨ÒµÊÔÌ⣩
8JvF4'zx 1. ÊԱȽÏTCRºÍBCR½á¹¹¼°Æäʶ±ð¿¹Ô¡¢ÁܰÍϸ°û»î»¯ÐźŵķÖ×Ó»úÀí¡££¨ÃâÒßѧרҵ£©¡£
l;_zX
N 2. ÊÔÊö°×Ѫ²¡ÃâÒßѧ·ÖÐÍÀíÂۺͷ½·¨µÄÑо¿½øÕ¹¡££¨ÑªÒº²¡Ñ§×¨Òµ£©¡£
:wtr{,9rZ 3. ÊÔÊöÖ×ÁöÒßÃçµÄÑо¿½øÕ¹¡££¨Ïû»¯ÄÚ¿Æ×¨Òµ£©¡£
doM}vh)6 Ò»¾Å¾Å°ËÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ
(NPDgR/
£¨ÃâÒßѧרҵºÍרҵ»ù´¡£©
^D`ARH Ò».Ãû´Ê½âÊÍ£¨Ã¿Ìâ3·Ö£¬¹²45·Ö£©
;`ZGiax 1.Co-stimulators (or co-stimulating molecules)
<tp\+v!u 2.NK-kB
_h;#\ )%~ 3.Immunoglobulin superfamily
:$eg{IXC" 4.antigen-presenting cell (APC)
v"x{oD$R 5.death domain
+Ja9p 6.CCR and CXCR
&Z
Ja}5k!r 7.Lectin (or mitogen)
QvB]?D#h 8.Clusters of differentiation, CD)
L\p@1N?K 9.B7 family
B/@9.a.c 10.Cytotoxic T lymphocyte, CTL)
SVvR]T&_ 11.IL-15 and IL-15 receptor (IL-15R)
P=ARttT`( 12.MHC restriction
3'(w6V 13.Affinity-chromatography
h9Zf4@w 14.Cyctosprin A, CsA
DFvLCGkDk 15.Antibody-dependent cell-mediated cytotoxicity, ADCC)
M[9]t(" ¶þ.ÎÊ´ðÌ⣨ÿÌâ10·Ö£¬¹²30·Ö£©
e%#8]$ 1.ºÎΪTh1ºÍ Th2ÑÇȺ£¿ÈçºÎ¼ì²â£¿ÔÚÁÙ´²ÉÏÓкÎÒâÒ壿
@WuB&uF=d 2.ÊÔÊöÃâÒßÇòµ°°×£¨Ig£©µÄ½á¹¹Ó빦ÄܵĹØÏµ¡£
1EW-%GQO 3.ÊԱȽÏTϸ°ûÊÜÌ壨TCR/CD3£©ÓëBϸ°ûÊÜÌ壨BCR£©µÄ×é³É¡¢½á¹¹¼°Æäʶ±ð ¿¹ÔµÄÌØµã¡£
,~@0IKIA
Q Èý.Ñ¡ÔñÎÊ´ðÌ⣨¸÷רҵ¿¼ÉúÖ»´ðÒ»µÀ±¾×¨ÒµÊÔÌ⣬25·Ö£©
z`b.~<P ÃâÒßѧרҵ£º
<fY<.X 1.ÊÔÊöB7/CD28, CTLA-4£¬CD40/CD40L£¬LFA-1/ICAM-1£¬CD2/LFA-3µÄ½á¹¹¡¢·Ö²¼ÒÔ¼°Ï໥×÷Óúó½éµ¼µÄÖ÷ÒªÉúÎïѧ¹¦ÄÜ¡£
a8fLj Ïû»¯ÄÚ¿Æ£º
?&Y3Fr)% 2.Ö×Áö¿¹Ô·ÖΪÄļ¸Àࣿ»úÌ忹Ö×ÁöÃâÒßÖ÷ÒªÓÐÄÄЩÒòËØ£¨»úÖÆ£©£¿¼òÊöÌá¸ß¿¹Ö×ÁöÃâÒßÑо¿µÄÂԲߡ£
; *G[3kk ѪҺ²¡Ñ§×¨Òµ£º
@nN+F,phx 3.ºÎΪ°×Ѫ²¡µÄÃâÒßѧ·ÖÐÍ£¿ºÎÎªÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£©£¿GVHR·¢ÉúµÄÖ÷ÒªÔÒò£¨Ìõ¼þ£©ÊÇʲô£¿
ye U4,Ko Ò»¾Å¾ÅÄê¾Å²©Ê¿ÉúÈëѧ¿¼ÊÔÊÔÌâ
Z+"%MkX0 (רҵ»ù´¡: ÃâÒßѧ)
uQ9/ 7"S Ò».Ãû´Ê½âÊÍ(ÿÌâ5·Ö,¹²45·Ö)
htg+V-, 1. ADCC(antibody dependent cell-mediated cytotoxicity)
'{EBK 2. »·æß¾úËØ(cyclosporin)
_\ n'uW$ 3. KIR(killer cell inhibitory receptor)
:xd&V%u` 4. HLDA(human leucocyte differentiation antigen)
Fs:l"5~>1 5. Interleukin 18(IL-18)
Py 8o8* H 6. ÕûºÏËØ(integrin)
Ch
` Omq 7. Fas/FasL
^r=#HQGt 8. FcR(ÃâÒßÇòµ°°×Fc¶ÎÊÜÌå)
?Gr<9e2Eo 9. ϸ°û¼äÕ³¸½·Ö×Ó(ICAM)
'w.:I
TJf 10. Th1/Th2
hD\C[C, 11. »ùÒòÒßÃç(DNAÒßÃç)
C<A82u;t%@ 12. chemokines and chemokine receptor
>fo &H_a 13. ÃâÒßÄÍÊÜ
,K7C2PV6 14. ¹²´Ì¼¤·Ö×Ó
GMOv$Tn-_L 15. ËÀÍö½á¹¹Óò(death domain)
iZ[o2Tre ¶þ.ÎÊ´ðÌâ(µÚ1¡¢2Ìâ¸÷18·Ö,µÚ3Ìâ19·Ö)
$y=sT({VVe 1. ÊԱȽÏɱÉËÐÔTϸ°û(CTL)Óë×ÔȻɱÉËϸ°û(NK)ÔÚɱÉ˰Ðϸ°û¹ý³ÌÖÐ,ʶ±ðϸ°û¶¾¼°½éµ¼ÃâÒß¹¦ÄÜÓкβ»Í¬?
vzaxi;S< 2. 70Äê´úÒÔÀ´,ÓйØIgºÍÌåÒºÃâÒßÑо¿´æÔÚÒÔϼ¸ÏîÖØ´ó·¢ÏÖºÍÍ»ÆÆ¶ø»ñµÃҽѧºÍÉúÎïѧŵ±´¶û½±,Çë·Ö±ð²ûÊöËüÃǵÄÀíÂÛÒâÒå¼°ÔÚҽѧʵ¼ùÖеÄÓ¦Óá£
vE?qF9I{$0 £¨1£©1972Ä꣺θµ°°×øºÍľ¹Ïµ°°×øˮ½âIg£¬»ñµÃFab¡¢Fc¡¢F£¨ab¡¯£©2µÈƬ¶Î
5n.4>yOY £¨2£©1977Ä꣺·ÅÉäÃâÒß·¨
1`_Mc ] £¨3£©1984Ä꣺ÁܰÍϸ°ûÔÓ½»ÁöºÍµ¥¿Ë¡¿¹Ìå
)." zBc# £¨4£©1987Äê: Ig»ùÒòµÄ½á¹¹
c<JJuG 3. ½üÄêÀ´ÔÚÖ×ÁöÃâÒßÑо¿ÁìÓòÖÐÓÐÄÄÐ©ÖØÒª½øÕ¹?ÊÔÊöµ±Ç°Ìá¸ß»úÌ忹Ö×ÁöÃâÒßµÄÖ÷Òª²ßÂÔ¡£
ZH:#~Zyj Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(ÃâÒßѧרҵ)
}SpMHR` ÎÊ´ðÌâ(ÿÌâ25·Ö)
@oYq.baHX 1. ÊԱȽÏTϸ°ûÊÜÌ壨TCR£©¡¢Bϸ°ûÊÜÌ壨BCR£©ºÍNKϸ°ûÊÜÌ壨NKCR£©µÄ×é³É£¬Ê¶±ðÅäÌåÒÔ¼°ÐźÅתµ¼µÄÒìͬµã¡£
uK(+WA 2. ÒÔÐØÏÙÒÀÀµ¿¹Ô´Ì¼¤»úÌå²úÉú¿¹ÌåµÄÃâÒßÓ¦´ðΪÀý£¬Tϸ°ûºÍBϸ°ûÊÇÈçºÎÏ໥×÷Óã¿ÓÐÄÄЩճ¸½·Ö×Ӻ͹²´Ì¼¤·Ö×Ó²ÎÓëT¡¢Bϸ°ûµÄÏ໥×÷Óã¿
wrsETB
c 3. Éö×ÛºÏÕ÷³öѪÈÈ(HFRS)²¡¶¾µÄ½á¹¹»ùÒòÒѾ¸ãÇå³þ,ΪÁË֤ʵHFRS²¡¶¾¸ÐȾ»úÌå(ÒÔBalb/CСÊóΪÀý)¿É²úÉúHFRS²¡¶¾ºËÒ¿ǵ°°×(NP)ÌØÒìÐÔCTL,²¢ÔÚÃâÒß·À»¤ÖÐÆðÖØÒª×÷ÓÃ,ÇëÓ¦ÓÃÃâÒßѧÀíÂۺͷ½·¨,Éè¼ÆÒ»ÏµÍ³ÊµÑé,¼ÓÒÔ֤ʵ¡£
2%vwC]A 4. Àý¾Ù¶þ¸ö½üÄêÀ´Ï¸°ûºÍ·Ö×ÓÃâÒßѧÑо¿ÖгöÏÖµÄеÄÈȵã,Çë·Ö±ðÆÀÊöÆäÑо¿ÒâÒå¡¢·¢Õ¹Ç÷ÊÆÒÔ¼°Ó¦ÓÃǰ¾°¡£